D K Hatsukami

Summary

Affiliation: University of Minnesota
Country: USA

Publications

  1. ncbi Exposure to a tobacco-specific lung carcinogen in adolescent versus adult smokers
    Louise A Hertsgaard
    University of Minnesota Transdisciplinary Tobacco Use Research Center, 2701 University Avenue Southeast, 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 17:3337-43. 2008
  2. ncbi Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products
    Dorothy K Hatsukami
    Department of Psychiatry, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55422, USA
    Tob Control 22:i36-i37. 2013
  3. ncbi Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation
    Katherine R Schiller
    Tobacco Research Programs, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414, USA
    Nicotine Tob Res 14:902-9. 2012
  4. ncbi Nicotine reduction revisited: science and future directions
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota, 717 Delaware St SE, Minneapolis, Minnesota 55414, USA
    Tob Control 19:e1-10. 2010
  5. ncbi Developing the science base for reducing tobacco harm
    Dorothy K Hatsukami
    University of Minnesota Transdisciplinary Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 9:S537-53. 2007
  6. ncbi Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products
    Dorothy K Hatsukami
    University of Minnesota Transdisciplinary Tobacco Use Research Center and Cancer Center, Minneapolis 55414, USA
    J Natl Cancer Inst 96:844-52. 2004
  7. ncbi Changing smokeless tobacco products new tobacco-delivery systems
    Dorothy K Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55414, USA
    Am J Prev Med 33:S368-78. 2007
  8. ncbi Effects of high dose transdermal nicotine replacement in cigarette smokers
    Dorothy Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, Department of Psychiatry, Minneapolis, MN 55414, United States
    Pharmacol Biochem Behav 86:132-9. 2007
  9. ncbi Toxicant exposure in cigarette reducers versus light smokers
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota, 2701 University Avenue Southeast, 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 15:2355-8. 2006
  10. ncbi Smokeless tobacco brand switching: a means to reduce toxicant exposure?
    D K Hatsukami
    University of Minnesota, Tobacco Use Research Center, 2701 University Avenue SE, Suite 201, Minneapolis, MN 55414, USA
    Drug Alcohol Depend 87:217-24. 2007

Research Grants

  1. Innovative Interventions for Smoking Cessation
    Dorothy Hatsukami; Fiscal Year: 2009
  2. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy Hatsukami; Fiscal Year: 2009
  3. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy K Hatsukami; Fiscal Year: 2010
  4. Innovative Interventions for Smoking Cessation
    Dorothy K Hatsukami; Fiscal Year: 2010
  5. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010
  6. TOBACCO EXPOSURE REDUCTION
    Dorothy Hatsukami; Fiscal Year: 2007
  7. TREATMENT OF SMOKELESS TOBACCO USERS
    Dorothy Hatsukami; Fiscal Year: 2005
  8. Interventions for Tobacco Dependent Adolescents
    Dorothy Hatsukami; Fiscal Year: 2005
  9. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010

Collaborators

Detail Information

Publications101 found, 100 shown here

  1. ncbi Exposure to a tobacco-specific lung carcinogen in adolescent versus adult smokers
    Louise A Hertsgaard
    University of Minnesota Transdisciplinary Tobacco Use Research Center, 2701 University Avenue Southeast, 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 17:3337-43. 2008
    ..This study compared carcinogen and nicotine exposure in adolescent and adult smokers across categories of CPD...
  2. ncbi Ending tobacco-caused mortality and morbidity: the case for performance standards for tobacco products
    Dorothy K Hatsukami
    Department of Psychiatry, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55422, USA
    Tob Control 22:i36-i37. 2013
    ..Performance standards and incentives should be provided so that tobacco companies are compelled to manufacture and market products with very low or almost non-existent toxicity (eg, nicotine-only products)...
  3. ncbi Comparing an immediate cessation versus reduction approach to smokeless tobacco cessation
    Katherine R Schiller
    Tobacco Research Programs, University of Minnesota, 717 Delaware Street SE, Minneapolis, MN 55414, USA
    Nicotine Tob Res 14:902-9. 2012
    ..In this study, we compared a reduction treatment approach with an immediate cessation approach in a population of ST users who reported no immediate plans to quit...
  4. ncbi Nicotine reduction revisited: science and future directions
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota, 717 Delaware St SE, Minneapolis, Minnesota 55414, USA
    Tob Control 19:e1-10. 2010
    ..This article provides an overview of the current science in the area of reduced nicotine content cigarettes and key conclusions and recommendations for research and policy that emerged from the deliberations of the meeting members...
  5. ncbi Developing the science base for reducing tobacco harm
    Dorothy K Hatsukami
    University of Minnesota Transdisciplinary Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 9:S537-53. 2007
    ..A description of the ongoing activities and challenges in these areas is provided, along with projected directions for the future...
  6. ncbi Evaluation of carcinogen exposure in people who used "reduced exposure" tobacco products
    Dorothy K Hatsukami
    University of Minnesota Transdisciplinary Tobacco Use Research Center and Cancer Center, Minneapolis 55414, USA
    J Natl Cancer Inst 96:844-52. 2004
    ..Although tobacco products with reportedly reduced carcinogen content are being marketed, carcinogen uptake in people who use these products has not been assessed systematically...
  7. ncbi Changing smokeless tobacco products new tobacco-delivery systems
    Dorothy K Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55414, USA
    Am J Prev Med 33:S368-78. 2007
    ....
  8. ncbi Effects of high dose transdermal nicotine replacement in cigarette smokers
    Dorothy Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, Department of Psychiatry, Minneapolis, MN 55414, United States
    Pharmacol Biochem Behav 86:132-9. 2007
    ..In most of these studies, only conventional doses of NRT have been tested and higher doses may be required to result in significant reductions in smoking and in biomarkers of exposure...
  9. ncbi Toxicant exposure in cigarette reducers versus light smokers
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota, 2701 University Avenue Southeast, 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 15:2355-8. 2006
    ..The goal of this study is to investigate the occurrence of compensatory smoking in reducers compared with light smokers by measuring toxicant exposure...
  10. ncbi Smokeless tobacco brand switching: a means to reduce toxicant exposure?
    D K Hatsukami
    University of Minnesota, Tobacco Use Research Center, 2701 University Avenue SE, Suite 201, Minneapolis, MN 55414, USA
    Drug Alcohol Depend 87:217-24. 2007
    ..ST brand switching may be a feasible alternative intervention for ST users interested in quitting but unwilling to stop ST use completely...
  11. ncbi Biomarkers to assess the utility of potential reduced exposure tobacco products
    Dorothy K Hatsukami
    University of Minnesota Cancer Center, Minneapolis, MN, USA
    Nicotine Tob Res 8:600-22. 2006
    ..Other promising biomarkers were discussed. No existing biomarkers have been demonstrated to be predictive of tobacco-related disease, which highlights the importance and urgency of conducting research in this area...
  12. ncbi Lack of effect of 5HT3 antagonist in mediating subjective and behavioral responses to cotinine
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota, 2701 University Avenue, 201, Minneapolis, MN 55414, USA
    Pharmacol Biochem Behav 75:1-7. 2003
    ..The data do not strongly support the hypothesis that 5HT(3) agonism is the mechanism by which cotinine offsets the effects of nicotine...
  13. ncbi Biomarkers to assess the utility of potential reduced exposure tobacco products
    Dorothy K Hatsukami
    Tobacco Use Research Center, University of Minnesota Cancer Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 8:169-91. 2006
    ..Other promising biomarkers were discussed. No existing biomarkers have been demonstrated to be predictive of tobacco-related disease, which highlights the importance and urgency of conducting research in this area...
  14. ncbi Methods to assess potential reduced exposure products
    Dorothy K Hatsukami
    University of Minnesota Cancer Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 7:827-44. 2005
    ..Although no currently available set of measures was thought to be sufficient for determining the relative health risk of potential reduced exposure products, this paper provides a blueprint for future research toward this end...
  15. ncbi Smokeless tobacco use: harm reduction or induction approach?
    Dorothy K Hatsukami
    Tobacco Use Research Center, Medical School, University of Minnesota, Minneapolis, MN 55414, USA
    Prev Med 38:309-17. 2004
    ..Use of ST as a smoking cessation method or as a means to reduce cigarettes has been proposed. The impact of using ST in these ways is relatively unknown...
  16. ncbi Harm reduction approaches to reducing tobacco-related mortality
    Dorothy K Hatsukami
    University of Minnesota, Tobacco Use Research Center, Minneapolis, Minnesota 55414, USA
    Annu Rev Public Health 25:377-95. 2004
    ..A significant amount of independent research is needed to inform policy decisions. Regulatory authority over potential reduced exposure products is also essential...
  17. ncbi Characteristics of cigarette smokers seeking treatment for cessation versus reduction
    Charlotte A Lemmonds
    Tobacco Use Research Center, University of Minnesota, 2701 University Avenue SE, Suite 201, Minneapolis, MN 55414, USA
    Addict Behav 29:357-64. 2004
    ..05). These results indicate that cigarette smokers seeking treatment for smoking reduction but not cessation may be more dependent smokers who experience more medical disorders...
  18. ncbi Safety and immunogenicity of a nicotine conjugate vaccine in current smokers
    Dorothy K Hatsukami
    Cancer Center, Tobacco Use Research Center, University of Minnesota Medical School, 2701 University Avenue SE, Minneapolis, MN 55414, USA
    Clin Pharmacol Ther 78:456-67. 2005
    ..The 30-day abstinence rate was significantly different across the 4 doses (P = .02), with the highest rate of abstinence occurring with 200 microg. The nicotine vaccine appears to be a promising medication for tobacco dependence...
  19. ncbi Smokeless tobacco reduction: preliminary study of tobacco-free snuff versus no snuff
    Dorothy K Hatsukami
    University of Minnesota, Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Nicotine Tob Res 10:77-85. 2008
    ....
  20. ncbi Nicotine addiction: past, present and future. Marian Fischman lecture given at the 2007 meeting of CPDD
    Dorothy K Hatsukami
    University of Minnesota, Transdisciplinary Tobacco Use Research Center, USA
    Drug Alcohol Depend 92:312-6. 2008
  21. ncbi Preliminary study on reducing oral moist snuff use
    Dorothy K Hatsukami
    University of Minnesota, Tobacco Use Research Center, 2701 University Ave SE, 210, Minneapolis 55414, USA
    Drug Alcohol Depend 70:215-20. 2003
    ..This pilot study examined whether reducing ST use using various methods can be achieved and whether this reduction results in lower exposure to carcinogens...
  22. ncbi Oral tobacco products: preference and effects among smokers
    Dorothy K Hatsukami
    Department of Psychiatry, University of Minnesota, 717 Delaware SE, Minneapolis, MN 55414, USA
    Drug Alcohol Depend 118:230-6. 2011
    ..lozenge). To date, little research has been conducted to determine how smokers respond to these products. The goal of this study was to examine if smokers prefer certain oral tobacco products based on their specific characteristics...
  23. ncbi Tobacco and nicotine product testing
    Dorothy K Hatsukami
    Department of Psychiatry, University of Minnesota Tobacco Research Programs, 717 Delaware St SE, Room 260, Minneapolis, MN 55414, USA
    Nicotine Tob Res 14:7-17. 2012
    ..These tools are also necessary for making assessments of the impact of new indications for medicinal products (other than cessation) but more importantly of tobacco products that may in the future be marketed as cessation tools...
  24. ncbi Immunogenicity and smoking-cessation outcomes for a novel nicotine immunotherapeutic
    D K Hatsukami
    Department of Psychiatry, University of Minnesota Tobacco Use Programs, Minneapolis, Minnesota, USA
    Clin Pharmacol Ther 89:392-9. 2011
    ..Its further development as a treatment for nicotine dependence is therefore justified...
  25. ncbi Effects of cigarette reduction on cardiovascular risk factors and subjective measures
    Dorothy K Hatsukami
    Transdisciplinary Tobacco Use Research Center, University of Minnesota, 2701 University Ave SE, Minneapolis, MN 55414, USA
    Chest 128:2528-37. 2005
    ..To assess the effect of continued smoking and smoking reduction on cardiovascular biomarkers (eg, WBC count, cholesterol concentrations, BP, heart rate)...
  26. ncbi Effects of sustained-release bupropion among persons interested in reducing but not quitting smoking
    Dorothy K Hatsukami
    Department of Psychiatry DKH, MK, University of Minnesota at Twin Cities, Minneapolis, Minnesota 55414, USA
    Am J Med 116:151-7. 2004
    ....
  27. ncbi Reduced nicotine content cigarettes: effects on toxicant exposure, dependence and cessation
    Dorothy K Hatsukami
    University of Minnesota Transdisciplinary Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Addiction 105:343-55. 2010
    ..To examine the effects of reduced nicotine cigarettes on smoking behavior, toxicant exposure, dependence and abstinence...
  28. ncbi Clinical trials methods for evaluation of potential reduced exposure products
    Dorothy K Hatsukami
    University of Minnesota Tobacco Use Research Center, Minneapolis, 55414, USA
    Cancer Epidemiol Biomarkers Prev 18:3143-95. 2009
    ....
  29. ncbi Tobacco addiction
    Dorothy K Hatsukami
    University of Minnesota, Comprehensive Cancer Center and Psychiatry, Minneapolis, Minnesota, USA
    Lancet 371:2027-38. 2008
    ..The future of treatment resides in improvement in patient matching to treatment, combination or novel drugs, and viewing nicotine addiction as a chronic disorder that might need long-term treatment...
  30. ncbi Characteristics of smokeless tobacco users seeking treatment
    D K Hatsukami
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Addict Behav 24:551-7. 1999
    ..A high frequency of users have smoked cigarettes as well as cigars. A supportive social environment for ST cessation exists for these individuals. These results have implications for ST treatment content...
  31. ncbi Sex and menstrual cycle differences in the subjective effects from smoked cocaine in humans
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Exp Clin Psychopharmacol 7:274-83. 1999
    ..Women, compared with men, had lower ratings on feel high, heart racing/pounding, and feel stimulated. Results suggest that there are significant sex and menstrual phase differences in the subjective effects of cocaine...
  32. ncbi Carvedilol affects the physiological and behavioral response to smoked cocaine in humans
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Drug Alcohol Depend 60:69-76. 2000
    ..These results suggest that acute treatment with carvedilol attenuates the physiological effects of smoked cocaine. The effects of carvedilol on cocaine self-administration need to be studied further...
  33. ncbi Predictors of cardiovascular response to smoked cocaine in humans
    M Sofuoglu
    Department of Psychiatry and Pharmacology, Health Science Center, University of Minnesota, Minneapolis 55415, USA
    Drug Alcohol Depend 57:239-45. 2000
    ..Whether these predictors of the cardiovascular response to smoked cocaine in the laboratory also predict cardiovascular complications from long-term cocaine use needs to be studied further...
  34. ncbi Pilot study on lower nitrosamine smokeless tobacco products compared with medicinal nicotine
    M Irene Mendoza Baumgart
    Transdisciplinary Tobacco Use Research Center, Cancer Center, University of Minnesota, Minneapolis, MN 55414, USA
    Nicotine Tob Res 9:1309-23. 2007
    ..However, the population effect of marketing of such products as reduced exposure/reduced risk is unknown. The need for further research in this area and regulation of tobacco products is evident...
  35. ncbi Exposure to nicotine and a tobacco-specific carcinogen increase with duration of use of smokeless tobacco
    S S Hecht
    Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Tob Control 17:128-31. 2008
    ..Smokeless tobacco is an efficient delivery vehicle for nicotine and can contain significant amounts of carcinogens. However, few studies have examined factors that might moderate levels of nicotine or carcinogen exposure...
  36. ncbi Individual differences in the subjective response to smoked cocaine in humans
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Am J Drug Alcohol Abuse 26:591-602. 2000
    ..The importance of these variables in maintaining the cocaine use behavior needs to be studied further...
  37. ncbi Urinary metabolites of a tobacco-specific lung carcinogen in nonsmoking hospitality workers
    Ozlem E Tulunay
    Tobacco Use Research Center, University of Minnesota, 2701 University Avenue Southeast, 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 14:1283-6. 2005
    ..The results of this study show that smoke exposure in bars and restaurants may have important health effects on nonsmoking employees, elicited by the increase in carcinogen levels...
  38. ncbi Effects of three doses of transdermal nicotine on post-cessation eating, hunger and weight
    J R Hughes
    University of Vermont, Department of Psychiatry, Burlington 05401 1419, USA
    J Subst Abuse 9:151-9. 1997
    ..We conclude nicotine replacement reduces post-cessation increases in eating but does not have a specific effect on sweet intake...
  39. ncbi Relationships between cigarette consumption and biomarkers of tobacco toxin exposure
    Anne M Joseph
    Section of General Internal Medicine 111 0, VA Medical Center, One Veterans Drive, Minneapolis, MN 55417, USA
    Cancer Epidemiol Biomarkers Prev 14:2963-8. 2005
    ....
  40. ncbi Treatment of spit tobacco users with transdermal nicotine system and mint snuff
    D K Hatsukami
    University of Minnesota, Department of Psychiatry, Minneapolis 55455, USA
    J Consult Clin Psychol 68:241-9. 2000
    ..No interaction effects were observed. At this time, the use of the nicotine patch and mint snuff should be primarily considered for the reduction of craving and withdrawal symptoms...
  41. ncbi Labetalol treatment enhances the attenuation of tobacco withdrawal symptoms by nicotine in abstinent smokers
    Mehmet Sofuoglu
    Department of Psychiatry, Yale University, USA
    Nicotine Tob Res 5:947-53. 2003
    ..The utility of adrenergic blockers, in combination with nicotine replacement therapies, for smoking cessation needs to be examined further in controlled clinical trials...
  42. ncbi Intravenous cocaine increases plasma epinephrine and norepinephrine in humans
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
    Pharmacol Biochem Behav 68:455-9. 2001
    ..These results suggest that plasma epinephrine and norepinephrine can be used as a measure for cocaine induced sympathoadrenal system activation...
  43. ncbi Biomarkers of tobacco exposure or harm: application to clinical and epidemiological studies. 25-26 October 2001, Minneapolis, Minnesota
    D K Hatsukami
    Department of Psychiatry, University of Minnesota, USA
    Nicotine Tob Res 5:387-96. 2003
    ..This conference reviewed both the general issues surrounding biomarker use and the current state of knowledge regarding the most widely studied and promising biomarkers...
  44. ncbi Oral spit tobacco: addiction, prevention and treatment
    D K Hatsukami
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Nicotine Tob Res 1:21-44. 1999
    ..Finally, the future directions are discussed in light of the limited amount of research that has been conducted in the smokeless tobacco area, particularly related to prevention and treatment...
  45. ncbi Withdrawal and pre-menstrual symptomatology during the menstrual cycle in short-term smoking abstinence: effects of menstrual cycle on smoking abstinence
    S S Allen
    Department of Family Practice and Community Health, University of Minnesota School of Medicine, Minneapolis, USA
    Nicotine Tob Res 1:129-42. 1999
    ..This suggests women may have greater difficulty quitting smoking in late luteal phase, and it seems prudent to recommend that women quit during the follicular phase of their cycle...
  46. ncbi Characteristics of research volunteers for inpatient cocaine studies: focus on selection bias
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis 55455, USA
    Addict Behav 25:785-90. 2000
    ..These results suggest that potential subjects who were accepted to our research studies may not accurately represent all potential subjects for several important subject characteristics...
  47. ncbi Are higher doses of nicotine replacement more effective for smoking cessation?
    J R Hughes
    Department of Psychiatry, University of Vermont, Burlington 05401 1419, USA
    Nicotine Tob Res 1:169-74. 1999
    ..s.). Our results are similar to most prior smaller studies; i.e., in heavy smokers higher doses increase quit rates slightly. Longer durations of treatment may be necessary to show greater advantages from higher doses...
  48. ncbi Effect of oral snus and medicinal nicotine in smokers on toxicant exposure and withdrawal symptoms: a feasibility study
    Michael Kotlyar
    University of Minnesota Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota, USA
    Cancer Epidemiol Biomarkers Prev 20:91-100. 2011
    ..Data are needed regarding how smokers interested in cessation would use these products, the levels of resultant toxicant exposure, and the feasibility of using these products as aids for tobacco cessation...
  49. ncbi Reducing tobacco harm: research challenges and issues
    Dorothy K Hatsukami
    Department of Psychiatry, University of Minnesota, Minneapolis, MN 55414, USA
    Nicotine Tob Res 4:S89-101. 2002
    ....
  50. ncbi Progesterone treatment during the early follicular phase of the menstrual cycle: effects on smoking behavior in women
    M Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
    Pharmacol Biochem Behav 69:299-304. 2001
    ..The effects of progesterone on nicotine dependence need to be studied further...
  51. ncbi Managing nicotine addiction
    Michael Kotlyar
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota at Twin Cities, Minneapolis 55455, USA
    J Dent Educ 66:1061-73. 2002
    ..This review summarizes the characteristics of nicotine addiction, reviews the pharmacological agents currently used to treat tobacco use disorder, and describes possible approaches to treat nicotine dependence in the future...
  52. ncbi Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers
    Stephen S Hecht
    Masonic Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street South East, Minneapolis, Minnesota 55455, USA
    Nat Rev Cancer 9:476-88. 2009
    ..It seems likely that logically constructed mixtures of these agents, developed from the ground up, will be necessary for the prevention of lung carcinogenesis...
  53. ncbi Quantitation of metabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone after cessation of smokeless tobacco use
    Stephen S Hecht
    University of Minnesota Cancer Center, Minneapolis, Minnesota 55455, USA
    Cancer Res 62:129-34. 2002
    ..These data may have considerable implications for understanding mechanisms of tumor induction by NNK...
  54. ncbi Smoking reduction fails to improve clinical and biological markers of cardiac disease: a randomized controlled trial
    Anne M Joseph
    Department of Medicine, University of Minnesota Medical School, Minneapolis, MN 55414, USA
    Nicotine Tob Res 10:471-81. 2008
    ..These results emphasize the importance of abstinence for smokers with heart disease to minimize health risks from tobacco...
  55. ncbi Metabolism of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone to its biomarker total NNAL in smokeless tobacco users
    Stephen S Hecht
    The Cancer Center and Transdisciplinary Tobacco Use Research Center, University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 17:732-5. 2008
    ..The results of this study also indicate that metabolic activation of NNK to intermediates that can react with DNA is its major pathway of metabolism in smokeless tobacco users...
  56. ncbi Stability of the nicotine metabolite ratio in ad libitum and reducing smokers
    Marc E Mooney
    University of Minnesota, Transdisciplinary Tobacco Use Research Center, 2701 University Avenue South East, Suite 201, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 17:1396-400. 2008
    ..Our objective was to evaluate the correlates and stability of the 3-HC to cotinine ratio in ad libitum and reducing smokers, using nicotine replacement therapy (NRT), over a period of months...
  57. ncbi Extensive metabolic activation of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in smokers
    Irina Stepanov
    The Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 17:1764-73. 2008
    ....
  58. ncbi Nicotine withdrawal and craving in adolescents: effects of sex and hormonal contraceptive use
    Patricia J Dickmann
    University of Minnesota, Tobacco Use Research Center, 2701 University Avenue SE, Suite 201, Minneapolis, MN 55414, USA
    Addict Behav 34:620-3. 2009
    ..Further, the use of hormonal contraceptives may impact the severity of craving. Addressing these different symptoms in adolescents may be useful in increasing smoking cessation rates in this special population of smokers...
  59. ncbi Patterns of self-selected smoking cessation attempts and relapse by menstrual phase
    Sharon S Allen
    Department of Family Medicine and Community Health, University of Minnesota, Medical School, Minneapolis, MN 55414, United States
    Addict Behav 34:928-31. 2009
    ..014). This confirms previous work suggesting quit dates in the F phase are associated with worse smoking cessation outcomes. Additional research is needed to investigate how this relationship may vary with the use of pharmacotherapy...
  60. ncbi Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal
    Michael Kotlyar
    Department of Experimental and Clinical Pharmacology, University of Minnesota College of Pharmacy, Minneapolis, MN 55455, USA
    Pharmacol Biochem Behav 83:370-9. 2006
    ..This study suggests that bupropion may be maintaining physiological measures of stress during the nicotine withdrawal period...
  61. ncbi Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype
    Jeannette Zinggeler Berg
    Department of Biochemistry, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    J Pharmacol Exp Ther 332:202-9. 2010
    ..Second, we provide the first convincing evidence that UGT2B10 is a key catalyst of these glucuronidation pathways in vivo...
  62. ncbi Similar exposure to a tobacco-specific carcinogen in smokeless tobacco users and cigarette smokers
    Stephen S Hecht
    Cancer Center and Transdisciplinary Tobacco Use Research Center, University of Minnesota Cancer Center, 420 Delaware Street Southeast, MMC 806, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 16:1567-72. 2007
    ..001). These results show similar exposures to the potent tobacco-specific carcinogen NNK in smokeless tobacco users and smokers. These findings do not support the use of smokeless tobacco as a safe substitute for smoking...
  63. ncbi Nicotine withdrawal and depressive symptomatology during short-term smoking abstinence: a comparison of postmenopausal women using and not using hormone replacement therapy
    Sharon S Allen
    Department of Family Practice and Community Health, University of Minnesota Medical School, Minneapolis 55455, USA
    Nicotine Tob Res 5:49-59. 2003
    ..This finding, though preliminary, may have clinical implications for postmenopausal women who attempt to quit smoking while on HRT, particularly since depressed mood following abstinence is associated with a relapse to smoking...
  64. ncbi Attitudes and knowledge about nicotine and nicotine replacement therapy
    Marc E Mooney
    Department of Psychiatry, University of Minnesota, Minneapolis, MN 55414, USA
    Nicotine Tob Res 8:435-46. 2006
    ..Changes in attitudes and knowledge were not significantly related to gum use or smoking cessation. Recommendations for the appropriate application of brief feedback are offered...
  65. ncbi Comparison of polymorphisms in genes involved in polycyclic aromatic hydrocarbon metabolism with urinary phenanthrene metabolite ratios in smokers
    Stephen S Hecht
    Transdisciplinary Tabacco Use Research Center and The Cancer Center, University of Minnesota, 420 Delaware Street Southeast, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 15:1805-11. 2006
    ..However, the results of this study indicate that genotyping is not an effective way to predict PAH metabolism at least as represented by PheT/HOPhe ratios...
  66. ncbi Effects of reduced cigarette smoking on the uptake of a tobacco-specific lung carcinogen
    Stephen S Hecht
    Transdisciplinary Tobacco Use Research Center and College of Pharmacy, University of Minnesota, Minneapolis, USA
    J Natl Cancer Inst 96:107-15. 2004
    ....
  67. ncbi Effects of reduced cigarette smoking on levels of 1-hydroxypyrene in urine
    Stephen S Hecht
    Transdisciplinary Tobacco Use Research Center and Cancer Center, University of Minnesota, Mayo Mail Code 806, 420 Delaware Street SE, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 13:834-42. 2004
    ....
  68. ncbi A comparison of urinary biomarkers of tobacco and carcinogen exposure in smokers
    Sharon E Murphy
    Transdisciplinary Tobacco Use Research Center, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 13:1617-23. 2004
    ..Whereas urinary concentrations of 1-hydroxypyrene were consistent across the four visits, the levels were not correlated with NNAL, anatabine, nicotine, or any nicotine metabolites...
  69. ncbi Transdermal nicotine use in postmenopausal women: does the treatment efficacy differ in women using and not using hormone replacement therapy?
    Sharon S Allen
    Department of Family Practice and Community Health, University of Minnesota Medical School, A682 Mayo Memorial Building, 420 Delaware St SE, MMC 381, Minneapolis, MN 55455, USA
    Nicotine Tob Res 6:777-88. 2004
    ....
  70. ncbi Inhibition of CYP2D6 activity by bupropion
    Michael Kotlyar
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Twin Cities Campus, Minneapolis, MN 55455, USA
    J Clin Psychopharmacol 25:226-9. 2005
    ..Bupropion is therefore a potent inhibitor of CYP2D6 activity, and care should be exercised when initiating or discontinuing bupropion use in patients taking drugs metabolized by CYP2D6...
  71. ncbi Similar uptake of lung carcinogens by smokers of regular, light, and ultralight cigarettes
    Stephen S Hecht
    Transdiciplinary Tobacco Use Research and Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA
    Cancer Epidemiol Biomarkers Prev 14:693-8. 2005
    ..The results are consistent with epidemiologic studies that show no difference in lung cancer risk in smokers of these cigarettes...
  72. ncbi Nicotine pharmacokinetics and subjective effects of three potential reduced exposure products, moist snuff and nicotine lozenge
    Michael Kotlyar
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA
    Tob Control 16:138-42. 2007
    ..To compare nicotine pharmacokinetics and subjective effects of three new smokeless tobacco potential reduced exposure products (PREPs; Ariva, Revel and Stonewall) with moist snuff (Copenhagen) and medicinal nicotine (Commit lozenge)...
  73. ncbi Depressive symptoms modulate the subjective and physiological response to cocaine in humans
    M Sofuoglu
    Department of Pharmacology, University of Minnesota, Minneapolis, MN 55414, USA
    Drug Alcohol Depend 63:131-7. 2001
    ..The implication of these results is that the presence of depressive symptoms may affect cocaine use behavior partly by being associated with an enhanced response to cocaine...
  74. ncbi Quantitation of 4-oxo-4-(3-pyridyl)butanoic acid and enantiomers of 4-hydroxy-4-(3-pyridyl)butanoic acid in human urine: A substantial pathway of nicotine metabolism
    S S Hecht
    University of Minnesota Cancer Center and Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 12:172-9. 1999
    ..These results provide new insights about nicotine metabolism in humans...
  75. ncbi Tobacco smoke exposure in nonsmoking hospitality workers before and after a state smoking ban
    Joni A Jensen
    Tobacco Use Research Center, University of Minnesota, 717 Delaware Street South East, Minneapolis, MN 55414, USA
    Cancer Epidemiol Biomarkers Prev 19:1016-21. 2010
    ..These results provide further support for the importance of protecting employees working in all venues...
  76. ncbi UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption
    Jeannette Zinggeler Berg
    Department of Biochemistry, Molecular Biology, and Biophysics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Cancer Epidemiol Biomarkers Prev 19:1423-31. 2010
    ..We report here the effect of a polymorphism in a UDP-glucuronsyltransferase, UGT2B10, on nicotine metabolism and consumption...
  77. ncbi Effects of smoking cessation on eight urinary tobacco carcinogen and toxicant biomarkers
    Steven G Carmella
    Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 22:734-41. 2009
    ....
  78. ncbi Efficacy of nicotine patch in smokers with a history of alcoholism
    John R Hughes
    Department of Psychiatry, University of Vermont, Burlington, 054001 1419, USA
    Alcohol Clin Exp Res 27:946-54. 2003
    ..Smokers with a history of alcohol dependence may have more difficulty quitting, might relapse to alcohol use, and might especially benefit from nicotine replacement therapy for smoking cessation...
  79. ncbi Racial/Ethnic disparities in the use of nicotine replacement therapy and quit ratios in lifetime smokers ages 25 to 44 years
    Steven S Fu
    Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center 152 2E, Minneapolis, MN 55417, USA
    Cancer Epidemiol Biomarkers Prev 17:1640-7. 2008
    ..Future prospective studies are needed to assess whether lower utilization of cessation treatments such as NRT contribute to the observed disparity in quit ratios for African Americans...
  80. ncbi Cigarette reduction: an intervention for adolescent smokers
    Karen Hanson
    University of Minnesota, Tobacco Use Research Center, Minneapolis, MN 55414, USA
    Drug Alcohol Depend 95:164-8. 2008
    ..05). The results suggest that reduction may be a potential aid to engage adolescents who are unable or unwilling to quit, but should not be an end goal. The effect of treatment methods on outcome measures did not differ significantly...
  81. ncbi Views on smoking cessation methods in ethnic minority communities: a qualitative investigation
    Steven S Fu
    Center for Chronic Disease Outcomes Research a VA HSR and D Center of Excellence, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Prev Med 44:235-40. 2007
    ..The purpose of this qualitative analysis is to increase our understanding of minority smokers' experiences and beliefs about guideline-recommended smoking cessation treatments...
  82. ncbi Effect of nonnicotine pharmacotherapy on smoking behavior
    M Kotlyar
    Department of Experimental and Clinical Pharmacology, College of Pharmacy, University of Minnesota at Twin Cities, Minneapolis 55455, USA
    Pharmacotherapy 21:1530-48. 2001
    ..Drugs that modulate noradrenergic neurotransmission (bupropion, nortriptyline, moclobemide) are more effective than those affecting serotonin (selective serotonin reuptake inhibitors, buspirone, ondansetron) or other neurotransmitters...
  83. ncbi Targeting treatments to special populations
    D K Hatsukami
    University of Minnesota, Department of Psychiatry, Minneapolis 55455, USA
    Nicotine Tob Res 1:S195-200; discussion S207-10. 1999
    ..Once population-specific treatment needs are identified, then the effects of tailored treatments in augmenting treatment success can be determined...
  84. ncbi Smokeless tobacco topography and toxin exposure
    Charlotte A Lemmonds
    Transdisciplinary Tobacco Use Research Center, University of Minnesota Cancer Center, Minneapolis 55414, USA
    Nicotine Tob Res 7:469-74. 2005
    ..001), particularly total dip duration, are significantly correlated with total cotinine, total nicotine, and total NNAL. These results suggest that how long a ST user has tobacco in his mouth is most predictive of tobacco toxin exposure...
  85. ncbi Beliefs and experiences regarding smoking cessation among American Indians
    Diana Burgess
    Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    Nicotine Tob Res 9:S19-28. 2007
    ..Results point to the need for community- and peer-based smoking cessation treatment in the American Indian community, including accurate information from trusted sources...
  86. ncbi Race and nicotine replacement treatment outcomes among low-income smokers
    Steven S Fu
    Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, Minnesota 55417, USA
    Am J Prev Med 35:S442-8. 2008
    ..This prospective, observational cohort study compared long-term cessation outcomes among four racial/ethnic groups after an aided quit attempt using nicotine replacement therapy (NRT)...
  87. ncbi Understanding smoking and cessation among Hmong smokers
    Diana Burgess
    Center for Chronic Disease Outcomes Research, Veterans Affairs Medical Center, Minneapolis, MN 55417, USA
    J Health Care Poor Underserved 19:442-51. 2008
    ....
  88. ncbi Ethylation and methylation of hemoglobin in smokers and non-smokers
    Steven G Carmella
    University of Minnesota Cancer Center, Minneapolis, MN 55455, USA
    Carcinogenesis 23:1903-10. 2002
    ..As levels of hemoglobin and DNA adducts often correlate, the results of this study support the proposal that cigarette smoke contains an as yet unidentified ethylating agent, which might be involved in DNA damage and tumor initiation...
  89. ncbi Quantitation of acrolein-derived (3-hydroxypropyl)mercapturic acid in human urine by liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: effects of cigarette smoking
    Steven G Carmella
    The Cancer Center and Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 20:986-90. 2007
    ..The results of this study clearly demonstrate that acrolein uptake in smokers is significantly higher than in nonsmokers and underline the need for further investigation of the possible relationship of acrolein uptake to lung cancer...
  90. ncbi The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users
    Mehmet Sofuoglu
    Yale University, School of Medicine, Department of Psychiatry, VA Connecticut Healthcare System, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, USA
    Addict Behav 30:1125-34. 2005
    ..Our findings support two dimensions in cocaine withdrawal symptoms with differential effects on cocaine dependence outcomes...
  91. ncbi Transdisciplinary science applied to the evaluation of treatments for tobacco use
    Timothy B Baker
    University of Wisconsin Medical School, USA
    Nicotine Tob Res 5:S89-99. 2003
    ..The potential benefits and costs of a transdisciplinary approach are discussed, along with selected research projects from the Transdisciplinary Tobacco Use Research Centers...
  92. ncbi Effectiveness of over-the-counter nicotine replacement therapy
    Lindsay F Stead
    JAMA 288:3109-10; author reply 3110. 2002
  93. ncbi Perceived risk of harm from cigarettes or smokeless tobacco among U.S. high school seniors
    Scott L Tomar
    University of Florida, Department of Community Dentistry and Behavioral Science, Gainesville, FL 32610 3628, USA
    Nicotine Tob Res 9:1191-6. 2007
    ..Those who perceived that using smokeless tobacco was riskier than smoking were even more likely to be current smokers (OR = 2.43; 95% CI 1.96-3.01). Effective methods for communicating accurate health risks to young people are needed...
  94. ncbi Race differences in nicotine dependence in the Collaborative Genetic study of Nicotine Dependence (COGEND)
    Zhehui Luo
    Department of Epidemiology, Michigan State University, MI, USA
    Nicotine Tob Res 10:1223-30. 2008
    ..The data support the hypothesis that the relationship between CPD and nicotine dependence as reflected in relapse varies by race, and that Black smokers are dependent at lower levels of CPD than Whites...
  95. ncbi Test of measurement invariance of the FTND across demographic groups: assessment, effect size, and prediction of cessation
    Eric O Johnson
    Behavioral Health Epidemiology, Division of Health, Social, and Economic Research, Research Triangle Institute International, PO Box 12194, 3040 Cornwallis Road, Research Triangle Park, NC 27709 2194, USA
    Drug Alcohol Depend 93:260-70. 2008
    ....
  96. ncbi Detecting longitudinal patterns of daily smoking following drastic cigarette reduction
    Bettina B Hoeppner
    Cancer Prevention Research Center, University of Rhode Island, USA
    Addict Behav 33:623-39. 2008
    ..46, p=.011, eta2=.115), underscoring their importance in maintaining reduced smoking rates. Time series-based typology demonstrated good sensitivity to the identification of meaningfully different trajectories...
  97. ncbi The association of a tobacco-specific biomarker and cigarette consumption and its dependence on host characteristics
    Jay H Lubin
    Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Boulevard, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 16:1852-7. 2007
    ..Variations in the ratio with host characteristics were generally similar to a recent epidemiologic analysis of effect modification of the association between lung cancer and cigarette smoking...
  98. ncbi Effective tobacco dependence treatment
    Michael C Fiore
    Department of Medicine and Center for Tobacco Research and Intervention, University of Wisconsin Medical School, 1930 Monroe St, Madison, WI 53711, USA
    JAMA 288:1768-71. 2002
  99. ncbi Effects of progesterone treatment on smoked cocaine response in women
    Mehmet Sofuoglu
    Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA
    Pharmacol Biochem Behav 72:431-5. 2002
    ..Further studies are warranted to examine the effects of progesterone treatment on cocaine dependence...
  100. ncbi Quantitation of an acetaldehyde adduct in human leukocyte DNA and the effect of smoking cessation
    Li Chen
    The Cancer Center and Transdisciplinary Tobacco Use Research Center, University of Minnesota, Minneapolis, Minnesota 55455, USA
    Chem Res Toxicol 20:108-13. 2007
    ..02). These results demonstrate that the major acetaldehyde DNA adduct can be reliably quantified by MS/MS methods in human leukocyte DNA and that cigarette smoking has a modest but significant effect on its levels...
  101. ncbi Association of cocaine withdrawal symptoms with more severe dependence and enhanced subjective response to cocaine
    Mehmet Sofuoglu
    Department of Psychiatry, VA Connecticut Healthcare System, School of Medicine, Yale University, 950 Campbell Ave, Bldg 36 116A4, West Haven, CT 06516, USA
    Drug Alcohol Depend 69:273-82. 2003
    ..4 mg/kg of smoked cocaine. These results suggest that history of cocaine withdrawal symptoms may be associated with enhanced cocaine responses and greater severity of cocaine dependence...

Research Grants23

  1. Innovative Interventions for Smoking Cessation
    Dorothy Hatsukami; Fiscal Year: 2009
    ..The results of this study will provide useful information on directions to pursue to improve our pharmacotherapies and behavioral treatments and to better understand the various aspects of addiction. ..
  2. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy Hatsukami; Fiscal Year: 2009
    ..The results from these studies will help determine the effects and feasibility of using oral tobacco products as both a cessation aid and a method to reduce individual health risk in cigarette smokers. ..
  3. Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..The results from these studies will help determine the effects and feasibility of using oral tobacco products as both a cessation aid and a method to reduce individual health risk in cigarette smokers. ..
  4. Innovative Interventions for Smoking Cessation
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..The results of this study will provide useful information on directions to pursue to improve our pharmacotherapies and behavioral treatments and to better understand the various aspects of addiction. ..
  5. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..This study would demonstrate the feasibility and impact of switching ST users to less toxic ST products. Together, these studies will help to guide important policy decisions to reduce the toll of tobacco-related disease. ..
  6. TOBACCO EXPOSURE REDUCTION
    Dorothy Hatsukami; Fiscal Year: 2007
    ..The results of research from this TTURC will provide the scientific basis for urgent policy, public education, and regulatory efforts to reduce tobacco harm. ..
  7. TREATMENT OF SMOKELESS TOBACCO USERS
    Dorothy Hatsukami; Fiscal Year: 2005
    ..The results of this study will determine the potential for an alternative and viable method for treating ST users. ..
  8. Interventions for Tobacco Dependent Adolescents
    Dorothy Hatsukami; Fiscal Year: 2005
    ....
  9. Novel Determinants and Measures of Smokeless Tobacco Use
    Dorothy K Hatsukami; Fiscal Year: 2010
    ..This study would demonstrate the feasibility and impact of switching ST users to less toxic ST products. Together, these studies will help to guide important policy decisions to reduce the toll of tobacco-related disease. ..